title: Outpatient Home-based Wet Wrap Dressings with Topical Steroids with Children with Severe Recalcitrant Atopic Dermatitis: A Feasibility Pilot Study.
abstract: Wet wrapping (WW) appears to be effective in severe atopic dermatitis (AD) in children resistant to topical treatment. Seventeen children were included and were directed to use WW every night (≥6 hr) until lesions disappeared, followed by maintenance treatment of two to three treatments per week. The mean Scoring Atopic Dermatitis (SCORAD) score at baseline was 48.9. After 1 month of treatment the mean SCORAD score was 18.9, and efficacy was maintained after 3 months of treatment. The majority of patients were satisfied (91.7%) with the WW treatment; 92% considered it to be much more effective than the previous treatments received. WW was easy to perform for 75% of patients, 83% of patients stated that it was better tolerated, and 17% considered it to be tolerated equally to dermatologic corticosteroids without WW. The home WW program was continued on a maintenance basis for 75% of patients. This open-label study showed that this program was a feasible and well-tolerated alternative for the treatment of severe, refractory AD in children and adolescents.
authors.affiliation: Department of Dermatology, Nantes University Hospital, Nantes, France.
authors.forename: Pauline
authors.initials: P
authors.lastname: Leloup
authors.affiliation: Department of Dermatology, Nantes University Hospital, Nantes, France.
authors.forename: Jean-François
authors.initials: JF
authors.lastname: Stalder
authors.affiliation: Department of Dermatology, Nantes University Hospital, Nantes, France.
authors.forename: Sébastien
authors.initials: S
authors.lastname: Barbarot
mesh_terms: D000293:Adolescent; D000553:Ambulatory Care; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use*; D001458:Bandages; D002648:Child; D002675:Child, Preschool; D003876:Dermatitis, Atopic / Q000188:drug therapy*; D004333:Drug Administration Routes; D004643:Emollients / Q000008:administration & dosage*; D005240:Feasibility Studies; D000068298:Fluticasone / Q000627:therapeutic use*; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D010865:Pilot Projects; D014867:Water
chemical_list: D000893:Anti-Inflammatory Agents; D004643:Emollients; D014867:Water; D000068298:Fluticasone